Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Jenner

Showing results (11-20 of 177) with videos related to

Pageof 18
Sort By:
European Journal of Neurology|July 27, 2023
Stalevo<sup>®</sup> : A pioneering treatment for OFF periods in Parkinsons diseasePeter Jenner
Parkinsonism & Related Disorders|February 8, 2003
The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's diseasePeter Jenner
Neurology|September 25, 2003
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complicationsPeter Jenner
Movement Disorders : Official Journal of the Movement Disorder Society|September 11, 2008
Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunitiesPeter Jenner
Expert Opinion on Investigational Drugs|July 12, 2005
Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's diseasePeter Jenner
Nature Reviews. Neuroscience|August 21, 2008
Molecular mechanisms of L-DOPA-induced dyskinesiaPeter Jenner
Movement Disorders : Official Journal of the Movement Disorder Society|July 22, 2014
A late appearance by the dopamine D-3 receptorPeter Jenner
Translational Neurodegeneration|May 15, 2015
Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the futurePeter Jenner
Movement Disorders : Official Journal of the Movement Disorder Society|September 19, 2017
A glimmer of light at the end of the tunnel?Peter Jenner
Neurology|January 14, 2004
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulationPeter Jenner
Pageof 18

Showing results (11-20 of 177) with videos related to

Sort By:
Pageof 18
European Journal of Neurology|July 27, 2023
Stalevo<sup>®</sup> : A pioneering treatment for OFF periods in Parkinsons diseasePeter Jenner
Parkinsonism & Related Disorders|February 8, 2003
The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's diseasePeter Jenner
Neurology|September 25, 2003
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complicationsPeter Jenner
Movement Disorders : Official Journal of the Movement Disorder Society|September 11, 2008
Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunitiesPeter Jenner
Expert Opinion on Investigational Drugs|July 12, 2005
Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's diseasePeter Jenner
Nature Reviews. Neuroscience|August 21, 2008
Molecular mechanisms of L-DOPA-induced dyskinesiaPeter Jenner
Movement Disorders : Official Journal of the Movement Disorder Society|July 22, 2014
A late appearance by the dopamine D-3 receptorPeter Jenner
Translational Neurodegeneration|May 15, 2015
Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the futurePeter Jenner
Movement Disorders : Official Journal of the Movement Disorder Society|September 19, 2017
A glimmer of light at the end of the tunnel?Peter Jenner
Neurology|January 14, 2004
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulationPeter Jenner
Pageof 18